DCN and cancer: Similar to TSKU, decorin (DCN) and biglycan (BGN) are two key SLRPs that have altered expression in various cancers with diverse clinical outcomes, and BGN serves as a potential marker of cancer proliferation associated with poor clinical outcome [25–27].